MEI Pharma, Inc.
MEIP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | -0.60 | 0.57 | 0.02 |
| FCF Yield | -6.32% | -14.95% | -22.39% | -22.37% |
| EV / EBITDA | -16.37 | 0.54 | 2.12 | 2.13 |
| Quality | ||||
| ROIC | -3.33% | -17.00% | -14.20% | -15.62% |
| Gross Margin | 0.00% | 50.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.24 | 0.92 | 1.27 | 1.37 |
| Growth | ||||
| Revenue 3-Year CAGR | -77.53% | -70.96% | -100.00% | -100.00% |
| Free Cash Flow Growth | -83.18% | 24.67% | 10.88% | 67.98% |
| Safety | ||||
| Net Debt / EBITDA | 2.70 | 6.26 | 7.38 | 6.88 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -26.49 | -94.26 | -879.34 |